Introduction {#s1}
============

Natural products with diverse chemical scaffolds have been recognized as an invaluable source of candidates in drug discovery and development for multiple complex diseases, including cancer. Berberine, a plant-derived compound isolated from medicinal plants such as Coptis chinensis and Hydrastis canadensis, had a long history of medicinal application in traditional Chinese medicine ([@B1]). As one of the main alkaloids, berberine has been reported to exert potentially beneficial effects on many cancer types, including breast cancer ([@B32]), bladder cancer ([@B68]), and hepatocarcinoma ([@B40]; [@B75]). For example, berberine had shown significant inhibitory effect on hepatocellular carcinoma cells and could reduce the volume and weight of tumors in an H22 transplanted tumor model in mice ([@B38]).

Based on collection of hundreds of berberine-related pharmacological literatures, we systematically summarized eight key mechanisms of anti-cancer effects of berberine, including cell death, cell invasion and metastasis, cell cycle arrest, cell growth, transcription factors, inflammatory factors, angiogenic, chemo-sensitivity, and radio-sensitivity ([**Figure 1**](#f1){ref-type="fig"} and [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}). Specifically, apoptosis (programmed cell death) plays a vital role in tumor cell development, differentiation, and proliferation ([@B45]). Recent study has revealed that berberine could induce apoptosis of human osteosarcoma U2OS cells through inhibiting the PI3K/Akt signaling pathway activation ([@B5]). In addition, anti-angiogenesis is a promising strategy for prevention and treatment of multicancer in preclinical or clinical studies in terms of many natural products ([@B31]; [@B35]). Previous *in vitro* and *in vivo* experiments have validated that berberine exerted anti-angiogenic effect through inhibiting various proinflammatory and pro-angiogenic factors, including vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), interleukin-2 (IL-2), and metalloproteinase inhibitor (TIMP) ([@B21]).

![Diagram illustrating the eight potential anti-cancer effects of berberine. Berberine exerts anti-cancer activities *via* targeting various cancer key protein targets, related to cell death, cell invasion and metastasis, cell cycle arrest, cell growth, transcription factors, inflammatory factors, angiogenic, chemo-sensitivity, and radio-sensitivity.](fphar-10-00857-g001){#f1}

Collectively, berberine with polypharmacology has demonstrated its broad anti-cancer properties through targeting various oncogenic pathways and targets. Therefore, systematic exploration of the drug targets of berberine is of great significance for understanding its anti-cancer mechanisms of action (MOAs) and for further excavating its novel cancer indications.

Systems pharmacology-based approaches, as an emerging interdiscipline that combines experimental assays and computational tools, have provided an alternative to understand the therapeutic mechanisms of complex diseases ([@B18]). Recent studies have demonstrated advanced discovery of new indications for natural products based on systems pharmacology approaches ([@B17]; [@B15]). For example, novel molecular mechanisms of several effective natural products (e.g., resveratrol, quercetin, caffeic acid, and wogonoside) for multiple complex diseases including multi-cancer types and age-related disorders have been identified and validated by various literatures and *in vitro* and *in vivo* experiments ([@B16]; [@B23]). Collectively, systems pharmacology-based approaches have been proved as an effective tool for exploring the poly-pharmacological actions of natural products towards various complex diseases.

In this study, we proposed a systems pharmacology infrastructure to identify new cancer indications of berberine and explore their molecular mechanisms ([**Figure 2**](#f2){ref-type="fig"}). Specifically, we constructed a global DTI network of berberine by integrating both experimentally reported DTIs obtained from literatures and DTIs computationally predicted by our previous predictive network models ([@B19]). Besides, a high-quality collection of significantly mutated genes (SMGs) for multiple cancer types was manually collected. On the basis of curated cancer SMGs and DTIs, we built statistical network models with high accuracy to prioritize new cancer indications of berberine and showcased its potential mechanisms. Overall, this study provides a useful systems pharmacology framework to interpret the multi-scale MOAs of berberine in multiple cancer type management, which may give some enlightenment for further treatment of cancer-associated diseases.

![Workflow of a systems pharmacology infrastructure for the identification of cancer indications and exploration of molecular mechanisms of berberine. **(A)** Construction of drug--target network for berberine, **(B)** manual curation of cancer significantly mutated genes (SMGs) for multiple cancer types, **(C)** performing network analyses to explore the anti-cancer mechanism of berberine, and **(D)** statistical network models for prioritizing novel anti-cancer indication of berberine through integrating computationally predicted and known drug targets into the curated cancer SMGs.](fphar-10-00857-g002){#f2}

Materials and Methods {#s2}
=====================

Collection of Known Targets for Berberine {#s2_1}
-----------------------------------------

Known targets of berberine were collected by extracting data from four data sources, including HIT ([@B70]), STITCH ([@B36]), BindingDB (accessed June 2016) ([@B20]), and ChEMBL ([@B2]). For STITCH, we only kept the targets with experimental evidence score higher than 0.7. We totally obtained 66 known targets *via* integrating the four available databases. Besides, we further gathered 238 extra targets of berberine by manually retrieving large-scale pharmacological literatures from PubMed (<https://www.ncbi.nlm.nih.gov>) with "berberine \[title\] and cancer" as search terms ([**Supplementary Table S2**](#SM1){ref-type="supplementary-material"}). After duplicated targets and DTIs were eliminated from non-*Homo sapiens*, 275 high-quality known DTIs were selected for further study ([**Supplementary Table S3**](#SM1){ref-type="supplementary-material"}).

Network-Based Target Prediction for Berberine {#s2_2}
---------------------------------------------

In a previous study, we have developed statistical network models to predict targets of natural products through a balanced substructure--drug--target network-based inference (bSDTNBI) approach ([@B18]). The bSDTNBI method utilizes resource-diffusion processes to prioritize potential targets for natural products through integrating known DTI network, drug--substructure linkages, and new input drug--substructure linkages ([@B63]). For a new input chemical, each of its substructures equally spreads resources to its neighbor nodes layer by layer, and targets obtaining final resources could be regarded as the potential targets of the new chemical. Four parameters (α = β = 0.1, γ = −0.5, and *k* = 2) of bSDTNBI were adopted based on a previous study ([@B64]). Among them, parameter α was introduced to balance the initial resource allocation of different node types, while β was used to adjust weighted values of different edge types. The third parameter γ was imported to balance the influence of hub nodes in resource-diffusion processes, and the fourth parameter κ denotes the number of resource-diffusion processes. We calculated four substructure items for each compound based on four types of molecular fingerprints from PaDEL-Descriptor (version 2.18) ([@B69]), including Substructure (FP4), Klekota-Roth (KR), MACCS, and PubChem. Among the four network models generated with different types of fingerprints, bSDTNBI_KR performed best with the highest values of precision (*P* = 0.049), recall (*R* = 0.752), precision enhancement (Ep = 27.02), recall enhancement (eR = 27.24), and the area under the receiver operating characteristic curve (AUC = 0.959). Finally, the best model built based on KR molecular fingerprint was selected to predict the new targets of berberine. The top 20 predicted candidates were used for further study ([**Supplementary Table S3**](#SM1){ref-type="supplementary-material"}).

Significantly Mutated Genes (SMG) for Multiple Cancer Types {#s2_3}
-----------------------------------------------------------

We collected 804 SMGs for 28 cancer types/subtypes from a previous study ([@B7]), including glioblastoma multiforme (GBM), serous ovarian adenocarcinoma (SOC), stomach adenocarcinoma (STAD), colorectal adenocarcinoma (CRAC), breast carcinoma (BRCA), uterine corpus endometrioid (UCEC), medulloblastoma (MBL), acute myeloid leukemia (AML), cutaneous melanoma (CM), lung squamous cell (SQCC), thyroid carcinoma (THCA), lung adenocarcinoma (LUAD), kidney clear cell (CCSK), head and neck squamous (HNSCC), small cell lung (SCLC), lower grade glioma (LGG), bladder carcinoma (BLCA), esophageal carcinoma (EC), prostate adenocarcinoma (PRAD), hepatocarcinoma (HCC), neuroblastoma (NBL), chronic lymphocytic leukemia (CLL), pancreas adenocarcinoma (PAC), multiple myeloma (MM), acute lymphocytic leukemia (ALL), non-small cell lung (NSCLC), diffuse large B-cell lymphoma (DLBCL), and pilocytic astrocytoma (PA). Considering a lack of statistical power if the number of SMG for specific cancer types is lower than 20, we further excluded ALL, NSCLC, DLBCL, and PA. All SMGs are annotated using gene Entrez ID, chromosome location, and the official gene symbols from the National Center for Biotechnology Information (NCBI) database ([@B73]). Finally, 24 cancer types/subtypes covering 804 SMGs were selected for further study ([**Supplementary Table S4**](#SM1){ref-type="supplementary-material"}).

Prioritizing Cancer Indications of Berberine {#s2_4}
--------------------------------------------

In this study, an integrated statistical network model was generated to prioritize cancer indication of berberine based on drug--target network and cancer SMGs ([@B7]; [@B27]). We assumed that berberine would exert high potential for the treatment of a specific cancer type if its targets tend to be SMGs of this cancer. For each cancer type/subtype, Fisher's exact test was utilized to calculate the statistical significance of the enrichment of SMGs for each cancer type in target profiles of berberine. The *P*-values were corrected by Benjamini--Hochberg method ([@B4]). We set a cutoff adjusted *P*-value threshold (*q*) \< 0.05 to define significantly predicted drug--cancer pairs.

Network Construction {#s2_5}
--------------------

To further explore the multi-scale MOAs of berberine in treating multiple cancer types, three types of networks were constructed by Cytoscape 3.2.1 software ([@B51]): 1) drug--target (D-T) network, which presents the relationship between berberine and its targets; 2) target--function (T-F) network, which illustrates the relationship between cancer-related biological processes and SMGs; and 3) drug--target--disease (D-T-D) network, which reflects a global view of the molecular mechanism of berberine against multiple cancer types. After network analysis, the SMGs were further mapped to DAVID database (<https://david.ncifcrf.gov/summary.jsp>) for extracting the canonical pathways that were highly associated with these targets ([@B13]). Finally, circos plot was used to visualize the predicted cancer indications.

Results and Discussion {#s3}
======================

Construction of the Drug--Target (D-T) Network for Berberine {#s3_1}
------------------------------------------------------------

The constructed drug--target interaction network ([**Figure 3**](#f3){ref-type="fig"}) of berberine contains 289 interactions, including 275 known targets and 20 predicted targets ([**Supplementary Table S3**](#SM1){ref-type="supplementary-material"}). *In vitro* and *in vivo* assays in previous studies have validated that five out of the 20 predicted targets could be mediated by berberine, indicating high accuracy of our target prediction approach. These five predicted targets are caspase-3 (CASP3) ([@B44]), cellular tumor antigen p53 (TP53) ([@B50]), caspase-9 (CASP9) ([@B72]), nuclear factor NF-kappa-B p105 subunit (NFKB1) ([@B71]), and mitogen-activated protein kinase 1 (MAPK1) ([@B52]).

![Drug--target (D-T) network of berberine composed of known and predicted targets. The predicted targets were obtained by a balanced substructure--drug--target network-based inference (bSDTNBI) approach. This network includes 289 drug--target interactions connecting berberine and 51 protein targets encoded by significantly mutated genes (SMGs).](fphar-10-00857-g003){#f3}

We further mapped the 289 protein targets of berberine into the curated cancer SMGs, resulting in 51 cancer-related targets encoded by SMGs ([**Supplementary Table S3**](#SM1){ref-type="supplementary-material"}). Accumulating evidences indicate that berberine may exert anti-cancer effects through regulating these targets. For instance, signal transducer and activator of transcription 3 (STAT3) are important in various phases of the tumor development, including tumor cell proliferation, survival, invasion, immunosuppression, and inducing and maintaining a pro-carcinogenic inflammatory microenvironment ([@B14]). A previous study has showed that berberine suppressed tumorigenicity and growth of nasopharyngeal carcinoma (NPC) cells by inhibiting STAT3 activation ([@B56]). Recently, a strategy targeting tumor suppressors and apoptosis-related genes provides a rationale for developing more effective approaches and agents for cancer prevention ([@B53]; [@B41]; [@B66]). Berberine has been observed to activate expression of many tumor apoptosis-related proteins, including caspase-8 (CASP8), tumor necrosis factor-a (TNF-a), and p38 MAPK, and thus induced apoptosis of HeLa cells ([@B42]). Besides, it has been reported that berberine can decrease expression of mitochondrial-dependent anti-apoptotic factors such as B-cell lymphoma-2 (Bcl-2) and Bcl-2-like protein 1 (BCL2L1) in KB human oral cancer cells ([@B33]).

Taken together, the observed polypharmacological profiles of berberine motivated us to elucidate its anti-cancer mechanism through systems pharmacology analysis on the interaction between berberine and 51 SMGs.

Elucidating Molecular Mechanisms of Berberine in Cancer Prevention and Treatment {#s3_2}
--------------------------------------------------------------------------------

### Target--Function Network {#s3_2_1}

As depicted in [**Figure 4**](#f4){ref-type="fig"}, the target--function (T-F) network is composed of 230 T-F pairs connecting 51 SMG targets and 8 cancer-related functional modules based on the DAVID analysis ([**Supplementary Table S5**](#SM1){ref-type="supplementary-material"}). The eight functional modules include anti-cancer action associated with sustaining proliferative signaling ([@B24]), resisting cell death ([@B8]), deregulating cellular energetics ([@B54]), enabling replicative immortality ([@B65]), avoiding immune destruction ([@B28]), genome instability and mutation ([@B39]), angiogenesis ([@B29]), and activating invasion and metastasis ([@B55]). On average, each SMG target is involved in six cancer-related functional modules. We found that 25 out of 51 SMG targets are associated with more than five functional modules, indicating the higher potential role of these SMG targets related to cancers. Previous studies of berberine in cancer validated the functional analysis of our T-F network. For instance, berberine could induce cell cycle arrest involved in sustaining proliferative signaling in cholangiocarcinoma KKU-213 and KKU-214 cell lines ([@B49]). Berberine was reported to inhibit metastasis and tumor-induced angiogenesis in human cervical cancer cells as well ([@B9]).

![Target--function (T-F) network demonstrating the relationship between cancer-related biological processes and SMGs. A functional module is linked to a target if the target is involved in mechanism of anti-cancer action.](fphar-10-00857-g004){#f4}

### KEGG Enrichment Analysis {#s3_2_2}

In order to further elucidate molecular mechanisms of berberine in cancer prevention and treatment, we performed KEGG pathway enrichment analysis based on the 51 SMGs. After pathways with adjusted *P* (*q*) value higher than 0.05 were excluded, 56 enriched pathways related to cancer pathogenesis were obtained ([**Supplementary Table S6**](#SM1){ref-type="supplementary-material"}).

Among 56 pathways, PI3K-Akt (hsa04151; *q* = 2.0 × 10^−12^), p53 (hsa04115; *q* = 2.7 × 10^−9^), HIF-1 (hsa04066; *q* = 3.9 × 10^−9^), FoxO (hsa04068; *q* = 4.9 × 10^−9^), VEGF (hsa04370; *q* = 5.7 × 10^−7^), MAPK (hsa04010; *q* = 2.5 × 10^−6^), Ras (hsa04014; *q* = 6.4 × 10^−6^), Jak-STAT (hsa04630; *q* = 9.9 × 10^−4^), mTOR (hsa04150; *q*= 1.5 × 10^−2^), AMPK (hsa04152; *q* = 1.9 × 10^−2^), and NF-kappa B (hsa04064; *q* = 4.0 × 10^−2^) signaling pathways have been confirmed to be associated with berberine in previous literatures ([**Table 1**](#T1){ref-type="table"}). For example, berberine was reported to inhibit cellular growth and promotes apoptosis by down-regulating PI3K/Akt signaling pathway in breast cancer SKBR-3 cells and hepatoma HepG2 cells ([@B40]; [@B37]). *In vitro* and *in vivo* assays revealed that berberine sensitized drug-resistant breast cancer to doxorubicin (DOX) chemotherapy and directly induced apoptosis through the dose-orchestrated AMPK signaling pathway ([@B46]). Berberine also induces autophagic cell death through inhibition of mTOR-signaling pathway by suppressing Akt activity and up-regulating P38 MAPK signaling in HepG2 and MHCC97-L cells ([@B60]). The rest of the 45 enriched pathways prompt the potential anti-cancer acting mechanisms that may be mediated by berberine, which deserve to be validated by experimental assays in the future.

###### 

Summary of the 11 enriched pathways validated to be mediated by berberine in previous literatures.

  Pathway ID   Pathway name                   Genes                                                                                                                          *P* **-value**   PMID
  ------------ ------------------------------ ------------------------------------------------------------------------------------------------------------------------------ ---------------- --------------------
  hsa04151     PI3K-Akt signaling pathway     EGFR, HRAS, PIK3CB, MET, TP53, RAF1, BCL2L1, CDK4, KDR, AKT1, CDKN1A, CCND1, KRAS, CDKN1B, CCND3, BCL2, RAC1, MTOR, MYC, FN1   2.03E−12         27081456\|25212656
  hsa04115     p53 signaling pathway          CDKN1A, CCND1, CCND3, CASP8, SERPINE1, TP53, APAF1, FAS, CDK4, ATM                                                             2.66E−09         20455200
  hsa04066     HIF-1 signaling pathway        AKT1, EGFR, HRAS, CCND1, KRAS, PIK3CB, ERBB2, TP53, RAF1, RB1, CDK4                                                            3.89E−09         28775788
  hsa04068     FoxO signaling pathway         AKT1, EGFR, HRAS, CCND1, KRAS, PIK3CB, ERBB2, TP53, RAF1, MLH1, CDH1, MYC                                                      4.88E−09         24766860\|29360760
  hsa04370     VEGF signaling pathway         TNF, MAPK14, BCL2, RAC1, TP53, APAF1, BCL2L1, CASP1                                                                            5.72E−07         23869238
  hsa04010     MAPK signaling pathway         AKT1, EGFR, HRAS, CCND1, KRAS, PIK3CB, ERBB2, TP53, RAF1, MLH1, CDH1, MYC                                                      2.45E−06         19492307\|25212656
  hsa04014     Ras signaling pathway          AKT1, EGFR, HRAS, CCND1, KRAS, PIK3CB, ERBB2, TP53, RAF1, RB1, CDK4                                                            6.42E−06         25212656\|23159854
  hsa04630     Jak-STAT signaling pathway     AKT1, HRAS, KRAS, PIK3CB, JUN, RAC1, RAF1                                                                                      9.90E−04         26463023
  hsa04150     mTOR signaling pathway         TNF, CASP8, APAF1, CASP1                                                                                                       1.50E−02         23159854\|20830746
  hsa04152     AMPK signaling pathway         EGFR, MAPK14, JUN, RAC1, MET                                                                                                   1.88E−02         28775788
  hsa04064     NF-kappa B signaling pathway   TNF, CASP8, APAF1, CASP1                                                                                                       3.97E−02         19107816

### Drug--Target--Diseases Network {#s3_2_3}

We further built a drug--target--diseases (D-T-D) network *via* mapping 51 SMGs targeted by berberine into multiple cancers. As shown in [**Figure 5**](#f5){ref-type="fig"}, the 51 SMGs are related to 24 types of cancer. On average, each cancer links to nine SMGs, while each SMG is connected to 4.6 cancer types. Network analysis showed that the top 6 SMGs connected to the largest number of cancer types are cellular tumor antigen p53 (TP53), gTPase KRas (KRAS), epidermal growth factor receptor (EGFR), retinoblastoma-associated protein (RB1), serine-protein kinase ATM (ATM), and cadherin-1 (CDH1). Among them, EGFR, a key significantly mutated gene of cancer, is involved in the pathological mechanism of 13 cancer types, including LUAD, HNSCC, SQCC, EC, UCEC, PRAD, BRCA, CCSK, CLL, STAD, LGG, CRAC, and GBM. Previous studies confirmed that berberine can inhibit EGFR signal pathway in several cancer types, including STAD ([@B58]), PRAD ([@B24]), and CRAC ([@B59]). Besides, berberine acts in specific tumor by regulating multiple SMGs. For instance, cellular tumor antigen p53 (TP53) ([@B62]), RAC-alpha serine/threonine-protein kinase (AKT1) ([@B41]), and cyclin-dependent kinase inhibitor 1B (CDKN1B) ([@B12]) are highly correlated with breast cancer. Accumulating evidences demonstrated that berberine can inhibit breast cancer by acting on SMGs such as TP53 ([@B34]; [@B54]), AKT1 ([@B37]), and CDKN1B ([@B47]).

![Drug--target--disease (D-T-D) network of berberine. This network shows 51 proteins of berberine encoded by SMGs of 24 types of cancer.](fphar-10-00857-g005){#f5}

Briefly, the D-T-D network demonstrated that SMGs targeted by berberine were closely related to multi-cancer types. In the following part, statistical systems pharmacology approach was employed to identify novel cancer indications of berberine and explore the molecular mechanisms.

### Systems Pharmacology-Based Prediction of Cancer Indications for Berberine {#s3_2_4}

As shown in [**Figure 6**](#f6){ref-type="fig"}, a statistical systems pharmacology framework is proposed to prioritize novel cancer indications of berberine based on Fisher's exact test analysis. We calculated the therapeutic potential of berberine in 24 cancer indications and obtained 18 cancer indications of which adjusted *P* (*q*) values are lower than 0.05 (*q* \< 0.05), including HCC (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 19.25), LUAD (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 9.35), BLCA (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 9.31), CM (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 9.29), HNSCC (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 8.52), SQCC (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 6.74), EC (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 6.66), UCEC (*q* \< 1.0 × 10^−5^; −Log10 (*q*) = 6.52), PRAD (*q* = 1.15 × 10^−5^; −Log10 (*q*) = 6.32), BRCA (*q* = 1.33 × 10^−5^; −Log10 (*q*) = 6.26), CCSK (*q* = 2.30 × 10^−5^; −Log10 (*q*) = 6.02), CLL (*q* = 0.55 × 10^−3^; −Log10 (*q*) = 4.64), STAD (*q* = 1.76 × 10^−3^; −Log10 (*q*) = 4.14), SCLC (*q* = 5.33 × 10^−3^; −Log10 (*q*) = 3.65), NBL (*q* = 1.29 × 10^−2^; −Log10 (*q*) = 3.27), LGG (*q* = 1.67 × 10^−2^; −Log10 (*q*) = 3.16), CRAC (*q* = 3.21 × 10^−2^; −Log10 (*q*) = 2.87), and SOC (*q* = 3.36 × 10^−2^; −Log10 (*q*) = 2.85) ([**Supplementary Table S7**](#SM1){ref-type="supplementary-material"}). As listed in [**Table 2**](#T2){ref-type="table"}, 10 out of the 18 predicted cancer indications of berberine were validated by reported experimental evidences, including HCC, LUAD, BLCA, EC, PRAD, BRCA, STAD, CRAC, and SOC, indicating the high accuracy of our systems pharmacology-based predictive method (success rate = 55.6%).

![Circos plot visualizes the predicted cancer indications of berberine. The red connected lines represent the calculated −Log~10~ (*q*) value of each berberine-cancer type pair based on Fisher's exact test, while the blue ones represent the corresponding number of overlapped targets. The predicted cancer indications with literature validation were highlighted in bold font. We classified the 18 predicted cancer indications into four neoplasm categories according to Medical Subject Headings (MeSH) system (<https://www.ncbi.nlm.nih.gov/mesh/68009371>).](fphar-10-00857-g006){#f6}

###### 

Relevant literature evidences of the 18 predicted cancer indications of berberine.

  Cancer type   *P*-value (Fisher test)   Adj-*P*    Negative logarithmic   PMID
  ------------- ------------------------- ---------- ---------------------- ------------------------------
  HCC           5.63E−20                  1.35E−18   17.87                  26081696\|25496992\|24942805
  LUAD          4.52E−10                  1.08E−08   7.96                   24766860\|26672764\|26503561
  BLCA          4.92E−10                  1.18E−08   7.93                   21545798\|23065570\|10418949
  CM            5.12E−10                  1.23E−08   7.91                   N/A
  HNSCC         3.03E−09                  7.27E−08   7.14                   26503508
  SQCC          1.82E−07                  4.37E−06   5.36                   N/A
  EC            2.18E−07                  5.23E−06   5.28                   28465635\|26667771\|21858113
  UCEC          3.03E−07                  7.27E−06   5.14                   N/A
  PRAD          4.77E−07                  1.15E−05   4.94                   16505103\|26698234\|25572870
  BRCA          5.53E−07                  1.33E−05   4.88                   29143794\|29414799\|28926092
  CCSK          9.58E−07                  2.30E−05   4.64                   N/A
  CLL           2.28E−05                  5.47E−04   3.26                   N/A
  STAD          7.32E−05                  1.76E−03   2.76                   27142767\|25837881\|18468407
  SCLC          2.22E−04                  5.33E−03   2.27                   N/A
  NBL           5.36E−04                  1.29E−02   1.89                   27235712\|19189664\|19096576
  LGG           6.95E−04                  1.67E−02   1.78                   N/A
  CRAC          1.34E−03                  3.21E−02   1.49                   23604974\|26463023\|25954974
  SOV           1.40E−03                  3.36E−02   1.47                   N/A

Among the 18 cancer indications, CM, HNSCC, SQCC, UCEC, CCSK, CLL, SCLC, NBL, and LGG are the unreported cancer indications of berberine, which deserve further preclinical validation. For example, cutaneous melanoma (CM), one of the most aggressive types of cancer, represents a major problem worldwide due to its high incidence and elevated degree of heterogeneity ([@B26]; [@B11]). Based on our predictive model, berberine exerted a high potential for anti-CM, with a significant *q* value \[*q* \< 1.23 × 10^−8^; −Log10 (*q*) = 9.29\]. Therefore, the potential of berberine in the prevention and treatment of CM deserves to be further validated.

### Case Study: Exploring the MOAs of Berberine on Hepatocarcinoma (HCC), Lung Adenocarcinoma (LUAD), and Bladder Carcinoma (BLCA) {#s3_2_5}

To further validate the accuracy of statistical network models and predicted anti-cancer targets of berberine, we selected three typical cancer types \[HCC (*q* = 5.63 × 10^−20^), LUAD (*q* = 4.52 × 10^−10^), and BLCA (*q* = 4.92 × 10^−10^)\] as case studies to illustrate their anti-cancer MOAs ([**Figure 7**](#f7){ref-type="fig"}).

![Drug--target--disease (D-T-D) network of berberine on hepatocarcinoma (HCC), lung adenocarcinoma (LUAD), and bladder carcinoma (BLCA). The thickness of the red dotted line represents the predicted association between berberine and three types of tumors.](fphar-10-00857-g007){#f7}

#### Hepatocellular Carcinoma {#s3_2_5_1}

HCC, the third leading cause of cancer death worldwide, has become one of the most common and prevalent human malignancies in the world ([@B44]). *In vitro* assays revealed that berberine can inhibit autophagy in hepatoma cell lines (e.g., HepG2 cells and MHCC97-L cells) by regulating multiple proteins \[e.g., mitogen-activated protein kinase 14 (MAPK14), TP53, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB)\] and pathways (e.g., P38 MAPK signaling), stimulating further development of derivatives for drug-base cancer prevention and treatment ([@B60]; [@B40]; [@B61]). In this study, Fisher's test showed that berberine played a significant role in treatment of liver cancer (*q* = 5.63 × 10^−20^). In addition, network analysis revealed that berberine bound with 27 HCC-related SMG targets, suggesting its underlying anti-cancer mechanisms of berberine ([**Figure 7**](#f7){ref-type="fig"}). *In vivo* or *in vitro* data have demonstrated that these SMGs are closely relevant to the treatment of cancer by berberine. For example, berberine can inhibit cell proliferation of HepG2, Hep3B, and SNU-182 through up-regulating protein expression of tumor suppressor genes, such as activating transcription factor 3 (ATF3) ([@B10]). Furthermore, study revealed that berberine inhibited expression of BCL2, thus reducing autophagic cell death and mitochondrial apoptosis in liver cancer cells, such as HepG2 and MHCC97-L cells ([@B25]).

#### Lung Adenocarcinoma {#s3_2_5_2}

LUAD is one of the leading causes of cancer-related death both men and women in the United States. Approximately two million people are diagnosed with lung cancer each year ([@B57]). Berberine was predicted to have anti-LUAD potential (*q* = 4.52 × 10^−10^). Some previous *in vivo* and *in vitro* studies confirmed our prediction ([@B43]; [@B74]). Furthermore, berberine is currently being assessed as an anti-LUAD drug in clinical trials (NCT03486496). As shown in [**Figure 7**](#f7){ref-type="fig"}, berberine interacts with 13 LUAD-related SMGs (e.g., matrix metalloproteinase-2), indicating the underlying MOAs of anti-LUAD of berberine. Matrix metalloproteinases (MMPs), one target displayed in our network, is the major protease of LUAD and is associated with tumor invasion and metastasis ([@B22]). Study on human lung cancer cell line A549 confirmed that berberine inhibited invasion and growth of tumor cells through decreasing productions of matrix metalloproteinase-2 (MMP2) ([@B48]).

#### Bladder Carcinoma {#s3_2_5_3}

BLCA is the most common cancer of the urinary system in the United States ([@B30]). In our network model, berberine is predicted to have a significant relationship with BLCA (*q* = 4.92 × 10^−10^). Meanwhile, our network indicated that berberine interacts with 17 BLCA-related SMGs (e.g., HRAS). According to previous study, the oncogenic ras genes GTPase HRas (HRAS) mutations, endogenously expressed in T24 bladder cancer cell line, were associated with grades and stages of BLCA detected in more than 35% of patients ([@B3]). Berberine inhibited cell proliferation and induced cell cycle arrest and apoptosis in BLCA by inhibiting oncogenic H-Ras pathway in BIU-87 and T24 cell lines ([@B68]).

Taken together, these three case studies against different cancer types (HCC, LUAD, and BLCA) indicate that systems pharmacology approach applied in this study is an effective method for exploring molecular mechanisms of anti-cancer effect of berberine. Meanwhile, the newly predicted tumor types might be promising to further investigate MOAs of berberine.

Conclusion {#s4}
==========

Berberine had been observed to exert multiple biological and pharmacological activities with potential benefits to a variety of complex diseases, including cancer. In this study, we proposed an integrated systems pharmacology infrastructure to identify cancer indications of berberine and explore the underlying molecular mechanisms. This work explores the following new anti-cancer characteristics of berberine: i) Through literature mining, we summarize eight mechanisms of anti-cancer effect of berberine; ii) global drug--target network of berberine is constructed by integrating large-scale experimentally reported targets and computationally predicted targets. Mechanisms of action (MOAs) of various anti-cancer effects of berberine are discussed through current drug--target network; iii) a statistical model is developed to prioritize novel cancer indications of berberine through integrating target profiles of berberine and significantly mutated genes in cancer.

Yet several limitations of our approach should be acknowledged. First, although we have integrated a wide range of DTIs from published literatures and publicly available databases, the incompleteness of current drug--target networks may still exist. Recent studies proved that integration of large-scale gene expression profiles of natural products may help to improve the performance of drug--target network model ([@B67]; [@B6]). Second, as it is extremely difficult to obtain information on the active sites of berberine and mutated domain of proteins from public sources, the current study could not explain the MOAs from a microcosmic point of view. Third, experimental assays should be performed to further validate the predicted targets and MOAs of anti-cancer effects of berberine in the future.

In summary, the systems pharmacology framework in this study has provided potential strategies to discover the polypharmacology effects of berberine for the prevention and treatment towards multiple cancers.
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